Opendata, web and dolomites
H2020 projects about "inhibitors"
The page lists 238 projects related to the topic "inhibitors".
| # | |||
|---|---|---|---|
| 1 | REGAIN | REgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss | 2015 |
| 2 | QUANTPATTERN | Quantitative analysis of Nodal/Lefty-mediated pattern formation | 2015 |
| 3 | DE-ORPHAN | DEtermination of Orphan Receptor PHysiological Agonists and sigNals | 2015 |
| 4 | VEGFDANI | Novel enhancers of functional recovery after stroke | 2015 |
| 5 | CannaPreg | Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for the treatment of schizophrenia and psychotic syndromes | 2015 |
| 6 | EPIMAC | The next generation epigenetic medicine for inflammation | 2015 |
| 7 | HyMedPoly | Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications | 2015 |
| 8 | MULTISURF | MULTI-functional metallic SURFaces via active Layered Double Hydroxide treatments | 2015 |
| 9 | SalHyd5 | Characterization of Salmonella enterica hydrogenase-5 biosynthesis for developing novel anti-infective compounds | 2015 |
| 10 | Pharmcophore-DOS | Pharmacophore guided diversity-oriented synthesis and its application in discovering inhibitors of protein-protein interactions between RAD51 and BRCA2 | 2015 |
| 11 | EpiNKT | Transcriptional and epigenetic control of innate-like T lymphocyte development | 2015 |
| 12 | BATTLE | The molecular basis of NleB-mediated bacterial virulence | 2016 |
| 13 | TARGEPILIVER | Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. | 2015 |
| 14 | MBLIs | New Approaches to Metallo-β-Lactamase Inhibitors | 2015 |
| 15 | PneumoCompetence | Unravelling the mechanisms of competence induction by antibiotic stress in Streptococcus pneumoniae | 2015 |
| 16 | APCINTERACTIONS | Molecular basis for securin and cyclin ubiquitylation by the anaphase-promoting complex (APC/C) | 2016 |
| 17 | 2G BIOPIC | Second Generation BIoethanol sustainable production based on Organosolv Process at atmospherIc Conditions | 2015 |
| 18 | jamclay | Chemical Tools to Probe the Role of Bromodomains in the Parasite Trypanosoma cruzi | 2016 |
| 19 | MaSCheNav | Mass Spectrometry-Based Chemoproteomic Profiling of Nav1.7, a Voltage-Gated Sodium Channel | 2015 |
| 20 | MELANOPARK | Investigating the LRRK2-melanin connection through phosphoproteomics of isogenic melanoma cells | 2015 |
| 21 | AND | Antibacterial (Nano)medicines Development | 2015 |
| 22 | CR-PHAGOCYTOSIS | Complement-mediated phagocytosis in neutrophils | 2015 |
| 23 | EPIRIN | EPIGENETIC REGULATION OF INFLAMMATION IN NAFLD | 2015 |
| 24 | IntestineUb | The role of Ubiquitin System on the homeostatic control of stem cell maintenance and differentiation in crypt stem cells | 2016 |
| 25 | FLUOROKEF | Incorporation of unnatural fluorinated amino acids to probe the function of the bacterial efflux system Kef in a cellular setting. | 2015 |
| 26 | ACM | Cholesterol metabolism as a driver of prostate cancer aggressiveness | 2015 |
| 27 | TITLY | Inhibition of the T-cell receptor signalling pathway for treatment of T-cell lymphoma | 2015 |
| 28 | PROVIST | PROTEASES VISUALIZATION DURING TUMOR PROGRESSION | 2016 |
| 29 | STTDAA | Synthesis of Truncated Tirandamycin A-D Derivatives as new Antihelminthic Agents | 2015 |
| 30 | CARDIOTOX | Predicting Cardiotoxicity Induced by Kinase Inhibitors: From Systems Biology to Systems Pharmacology | 2015 |
| 31 | SENSITIVITYMARKERS | Clinical validation of prognostic biomarkers of chemotherapy response in liquid biopsies | 2015 |
| 32 | SUMOblock | Blocking SUMO conjugation as drug discovery strategy. | 2015 |
| 33 | MyNano | Towards the design of Personalised Polymer-based Combination Nanomedicines for Advanced Stage Breast Cancer Patients | 2015 |
| 34 | REGiREG | Regulating the immune regulators: targeting adaptive immune control | 2015 |
| 35 | ZF-MEL-CHEMBIO | Chemical Biology in Zebrafish: Drug-Leads and New Targets in the Melanocyte Lineage and Melanoma | 2015 |
| 36 | RABIOPRED | RABIOPRED - Clinical validation of BIOmarker assay to PREDict treatment response in Rheumatoid Arthritis (RA) patients | 2015 |
| 37 | US4GREENCHEM | Combined Ultrasonic and Enzyme treatment of Lignocellulosic Feedstock as Substrate for Sugar Based Biotechnological Applications | 2015 |
| 38 | LEONID | Lung cancEr fusiOn geNes: a new dIagnostic Device | 2015 |
| 39 | T6SS-PSEUDO-LIP | Type VI-dependent Pseudomonas aeruginosa phospholipases and host manipulation | 2016 |
| 40 | TRIGGDRUG | Reactions That Translate mRNA into Drug-like Molecules | 2016 |
| 41 | AUROMYC | N-Myc and Aurora A: From Protein Stability to Chromosome TopologyN-Myc and Aurora A: From Protein Stability to Chromosome TopologyMyc and Aurora A: From Protein Stability to Chromosome Topology | 2015 |
| 42 | Phd | Deciphering PI3K biology in health and disease | 2015 |
| 43 | HaemMetabolome | Deciphering the Metabolism of Haematological Cancers | 2015 |
| 44 | p38Cure | New breast cancer therapies based on available p38 MAPK inhibitors | 2015 |
| 45 | StemNicheOnWaveCrest | New therapies for myeloproliferative diseases based on multi-stage and -system analyses of the haematopoietic stem-cell niche | 2015 |
| 46 | BIOVALID | Clinical validation of the DiviTum assay in two high profile clinical studies in Europe | 2015 |
| 47 | Infarnosys | Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment | 2015 |
| 48 | CODIC | COmmercializing first-in-class dCTPase Inhibitors for treatment of hematological Cancers | 2016 |
| 49 | SWEETOOLS | Smart Biologics: Developing New Tools in Glycobiology | 2016 |
| 50 | SAFEIMMUNOSUPPRESS | Development of immunosuppressive treatments with better safety | 2016 |
| 51 | GvHDCure | Understanding the dynamics of the immune system to cure graft-versus-host disease (GvHD). | 2016 |
| 52 | EVI1inCancer | Overcoming the epigenetic and therapeutic barrier of EVI1-overexpressing cancers | 2016 |
| 53 | PEP-PRO-RNA | Peptide-derived bioavailable macrocycles as inhibitors of protein-RNA and protein-protein interactions | 2016 |
| 54 | PrecTherLSCC | Precision Therapies in Lung Squamous Cell Carcinoma | 2016 |
| 55 | HeartAtaK | Targeting the Anti-Target: From Structure to Drug in the heart Kv11.1 channel | 2016 |
| 56 | FCSSSLP | First Chemoselective Synthesis and Structural Studies of Lasso Peptides | 2016 |
| 57 | MRCKa in cancer | Targeting Cancer Cell Invasion and Metastasis by Inhibition of the Serine Kinase MRCKa | 2016 |
| 58 | BiCyHePepDi | Bicyclic hetero peptidimer - a novel molecule format for therapeutic peptides | 2016 |
| 59 | NORVAS | Therapeutic and Biomarker Potential of long non-coding RNAs in Vascular Disease | 2016 |
| 60 | ONCOINTRABODY | Targeting common oncogenes with intracellular monobodies | 2016 |
| 61 | Wnt and CRC | Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors | 2017 |
| 62 | 2MoveMate4Melanoma | A treatment for BRAF inhibitor resistant melanoma | 2016 |
| 63 | CHIKV-FBDD | Structural investigation into functionality of Chikungunya virus nsP2 in replication complex and screening of small molecules for its inhibition | 2016 |
| 64 | MERC | Molecular mechanisms regulating cardiovascular remodeling by Adamts1 | 2016 |
| 65 | PeptiCrad | Personalized oncolytic vaccines for cancer immunotherapy | 2016 |
| 66 | CHEMCHECK | CHECKPOINTS IN CHECK: Novel Chemical Toolbox for Local Cancer Immunotherapy | 2016 |
| 67 | LeukaemiaTargeted | Selecting genetic lesions with essential function for patients' leukaemia in vivo as targets for precision medicine | 2016 |
| 68 | BCM-UPS | Dissecting the role of the ubiquitin proteasome system in the pathogenesis and therapy of B-cell malignancies | 2016 |
| 69 | PLEIO-RANK | Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity | 2016 |
| 70 | CDK6-DrugOpp | CDK6 in transcription - turning a foe in a friend | 2016 |
| 71 | ZMOD | Blood Vessel Development and Homeostasis: Identification and Functional Analysis of Genetic Modifiers | 2016 |
| 72 | TNT-TUMORS | Therapeutic approaches to enhance innate immunity against Tumors | 2016 |
| 73 | SIDSCA | Defective DNA Damage Responses in Dominant Neurodegenerative Diseases | 2016 |
| 74 | TAROX | Targeting oxidative repair proteins for treatment of cancer and inflammation | 2016 |
| 75 | MARS | Mechanism of allosteric regulation of SHP2 phosphatase and its role in cancer and geneticdiseases: a multidisciplinary computational, structural and biological approach | 2017 |
| 76 | LSDiASD | Leveraging Small Demethylase inhibitors for Autism Spectrum Disorder | 2016 |
| 77 | AD-VIP | Alzheimer’s disease and AAV9: Use of a virus-based delivery system for vectored immunoprophylaxis in dementia. | 2016 |
| 78 | PDZnet | Unraveling Principles of PDZ-mediated Cell Signaling | 2016 |
| 79 | Sphingolead | Development of a potent dual GCS/GBA2 inhibitor as a best in class Gaucher therapeutic | 2016 |
| 80 | PolyP-FXII in cancer | The polyphosphate/factor-XII pathway in cancer-driven thrombosis and tumor growth | 2017 |
| 81 | THERACAN | Novel therapeutic strategies to treat pancreatic and lung cancer | 2017 |
| 82 | VGAP | The Viral Genome Associated Proteome | 2017 |
| 83 | TKI resistance | Resistance mechanisms to tyrosine kinase inhibitors in solid tumors | 2016 |
| 84 | NOTID | Novel treatment of inflammatory diseases | 2016 |
| 85 | CHEMMINE | Chemical proteome mining for functional annotation of disease relevant proteins | 2017 |
| 86 | TEDCIP | Targeting epigenetic demethylases: development of covalent inhibitors and PROTACs (Proteolysis Targeting Chimeras). | 2017 |
| 87 | LIGER | Identification of novel substrates for ubiquitin ligases involved in cell cycle and cell migration | 2017 |
| 88 | Targeting TopoII | Mechanistic studies of metal-dependent DNA cleavage in Type II topoisomerase toward therational design of novel anticancer drugs | 2017 |
| 89 | GlycoModels | 3D glyco-engineered models to address the role of glycosylation in gastric cancer clinical management | 2017 |
| 90 | RepliStressTiming | Impact of replicative stress on DNA replication timing control | 2017 |
| 91 | BRAINHIB | Integrated drug discovery approach to generate brain-penetrant inhibitors of glioblastoma cell proliferation | 2018 |
| 92 | CRISTONE | Targeting CRISPR-based HDAC inhibitors to histones: a new tool for assessing mechanisms of class I HDAC inhibitors and developing chemical probes. | 2017 |
| 93 | RHOMBOSMALPS | Enabling malaria rhomboid proteases as drug targets: usage of molecular cookie cutters to shape novel activity assays and inhibitors. | 2017 |
| 94 | DREMATURE | DNA repair mechanisms and therapy resistance of BRCA2-deficient cancers | 2018 |
| 95 | DELLATECH | New DELLA-based biotechnological tools for sustainable Agriculture | 2017 |
| 96 | TRIBBLES | Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma | 2018 |
| 97 | ENDOCAM | TARGETING ENDOTHELIAL CELL AND CANCER AMOEBOID MOVEMENT TO OVERCOME RESISTANCE TO ANTI-VEGF AND ANTI-PROTEASE THERAPIES | 2017 |
| 98 | SHAPPI | Scaffold hybridization approach targeting PPIs | 2017 |
| 99 | DNAmethAML | Investigation of aberrant DNA methylation in malignant haematopoiesis | 2018 |
| 100 | MSCFate | Fate of mammary stem cells during tumorigenesis and clinical implications | 2017 |
| 101 | SIRFUNCT | Chemical Tools for Unravelling Sirtuin Function | 2017 |
| 102 | PCAGED-KI | Photocaged Kinase Inhibitors as Molecular Tools for Investigating Neurodegenerative Diseases | 2017 |
| 103 | IVORIaN | RAS/C-RAF interaction: A new pharmacological target in Kras-driven lung cancer. | 2017 |
| 104 | LIsTEN | β-Lactams as flaviviral NS3 protease inhibitors | 2017 |
| 105 | MUTAnTS | A microfluidic high throughput approach to helicase biophysics | 2018 |
| 106 | MuSCel Genome | Muscle Specific C. elegans Genome in health and disease: finding novel factors in 3D organization | 2017 |
| 107 | FimH-Mech | The molecular mechanism of E. coli FimH pathogenicity | 2017 |
| 108 | SAMNets | Investigation of adaptive design and rewiring of Survival-Apoptosis-Mitogenic (SAM) signalling transduction network | 2017 |
| 109 | INSPirAUTOR | Understanding how Inositol Polyphosphates regulate autophagy and lipid body formation in photosynthetic organisms: crosstalk with TOR signaling. | 2018 |
| 110 | ONCOPHAGY | Novel Atg4B-inhibitors and dual [Atg4B-carbonic anhydrase]inhibitors for interfering with cytoprotective mechanisms of cancercells in the acidic tumor micro-environment. | 2017 |
| 111 | DUALITY | An Integrated Computational and Experimental Approach to Rapid Synthesis of Highly Selective Dual-Targeted HDAC/CK2, MMP2/CK2 Inhibitors | 2018 |
| 112 | PI3K-VAs | Activation of PI3K signalling in the pathogenesis of Vascular Anomalies | 2018 |
| 113 | altEJrepair | Characterisation of DNA Double-Strand Break Repair by Alternative End-Joining: Potential Targets for Cancer Therapy | 2017 |
| 114 | INTUMORX | Elucidation of intratumoral heterogeneity in Kras-driven cancers | 2017 |
| 115 | PERCAL | Chemical building blocks from versatile MSW biorefinery | 2017 |
| 116 | NO-ESKAPE | Addressing Antibiotic Resistance: New Strategies for Overcoming the ESKAPE Pathogens | 2017 |
| 117 | ChAMPioN | Game-changing Precision Medicine for Curing All Myeloproliferative Neoplasms | 2018 |
| 118 | Ub-BAC | Dissecting and targeting ubiquitin networks in the course of bacterial infections | 2017 |
| 119 | NOVITREP | Novel viral therapy through targeting DNA repair | 2017 |
| 120 | Tumor-Treg-Targeting | Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours | 2018 |
| 121 | onCOMBINE | Towards evidence-based combinations of approved and novel cancer drugs | 2017 |
| 122 | VIRO-FLOW | Enabling Technologies and Drug Discovery: Continuous Flow Processes to Discover Novel Antiviral Inhibitors | 2017 |
| 123 | TECNEC | Preclinical concept validation of tumor endothelial cell metabolism for novel anti-angiogenic therapy | 2017 |
| 124 | GlypStx | Glycoprotein-based inhibitors of shiga-like toxin | 2018 |
| 125 | MNEMONIC | Magnetic Enzyme Metal Organic Framework Composites | 2017 |
| 126 | GlycoEdit | New Chemical Tools for Precision Glycotherapy | 2017 |
| 127 | CESYDE | Ceramide Synthases in Diabetic Beta Cell Demise | 2018 |
| 128 | EnDurCrete | New Environmental friendly and Durable conCrete, integrating industrial by-products and hybrid systems, for civil, industrial and offshore applications – EnDurCrete | 2018 |
| 129 | OMVCRC | Engineered bacterial Outer Membrane Vesicles (OMVs) for colorectal cancer immunotherapy | 2018 |
| 130 | Drug the bug | Identification of novel inhibitors to prevent microbial production of pro-diabetic metabolites | 2017 |
| 131 | Brain2Bee | How dopamine affects social and motor ability - from the human brain to the honey bee | 2018 |
| 132 | NovAnI | Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies | 2018 |
| 133 | NovInDXS | Development of novel inhibitors of the anti-infective target DXS using dynamic combinatorial chemistry (DCC) | 2018 |
| 134 | BIONICS | A biomimetic and neuroprotective delivery nanocapsule for the targeted treatment of post-ischemic stroke effects | 2018 |
| 135 | inhibitAUTO | Towards a New Frontier in Autophagy Inhibition: The Development of a Novel Class of ChemicalProbes and Identification of Their Associated Biological Target | 2018 |
| 136 | SYNFOS | Synthetic toolkit for fragment oriented synthesis | 2018 |
| 137 | IMMUNOMARK | Omics integration for precision cancer immunotherapy | 2018 |
| 138 | FINDER | FINDER: FIghtiNg DEngue viRus, a novel strategy for the development of fully protective antiviralsthat act by disrupting the DENV NS3/NS5 interaction | 2018 |
| 139 | ChemRAS | Chemical probing of transcriptional RAS effectors | 2019 |
| 140 | CrysPINs | Crystal structures of PIN proteins - CrysPINs | 2018 |
| 141 | EcoGemCoat | Smart anticorrosion coatings based on nanocontainers loaded with novel, eco-friendly cationic gemini surfactants as efficient corrosion inhibitors for carbon steel in seawater. | 2018 |
| 142 | EMBRACE | Elucidating Mechanisms of Bladder Cancer Metastasis | 2018 |
| 143 | UB-RASDisease | The ubiquitin system in RAS-driven disease | 2018 |
| 144 | Za-AV | Determination of physiologically relevant RNA substrate(s) and design of small-molecule inhibitors for Zα domains as potential intervention strategies for viral infections and autoimmunity | 2018 |
| 145 | Mtb CoaBC | CoaBC from the Coenzyme A pathway of Mycobacterium tuberculosis as an antimicrobial drug target | 2018 |
| 146 | UTILIUM | Unraveling The Immune Landscape In Uveal Melanoma | 2018 |
| 147 | rSAMs-NANO | Nanoparticles with switchable shells for virus sensing and inhibition | 2018 |
| 148 | Proteasome in cancer | Identification of the proteasome machinery targets in human cancer | 2018 |
| 149 | Target-N2O | Targeting N2O emission hot-spots in dairy pastures for mitigation action: microbes, stable isotope methods and modelling | 2018 |
| 150 | RET PHOTOSWITCH | THE DEVELOPMENT OF NOVEL PHOTOSWITCHABLE KINASE INHIBITORS | 2018 |
| 151 | ProCenDecl | Synthesis and validation of chemical Probes for Centrosome Declustering: development of potent and selective anti-cancer agents. | 2019 |
| 152 | INFLA-AID | The role of NLRC4 inflammasome in autoinflammatory diseases | 2018 |
| 153 | MATURE-NK | MAnufacturing of TUmour-REactive Natural Killer cells | 2018 |
| 154 | HOPE | Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6 | 2018 |
| 155 | SelectiveTGFb-inhib | Pro-tumorigenic effects of TGFb - elucidation of mechanisms and development of selective inhibitors | 2018 |
| 156 | ADDPRIME | Multifunctional smart inhibitors for anti-corrosive coatings, enabling a significant reduction of maintenance costs on metallic surfaces | 2018 |
| 157 | iFermenter | iFERMENTER - CONVERSION OF FORESTRY SUGAR RESIDUAL STREAMS TO ANTIMICROBIAL PROTEINS BY INTELLIGENT FERMENTATION | 2018 |
| 158 | PaSION | A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy | 2018 |
| 159 | CICURE | Increasing complex I stability as a cure for mitochondrial diseases | 2018 |
| 160 | STIMUNO | Searching for novel strategies improving cancer immunotherapy | 2019 |
| 161 | INTEGRATA | Integrating chemical and biological approaches to target NAD production and signaling in cancer | 2018 |
| 162 | NextGen IO | Exploiting the hypoxia response in T cells for Next-Generation Immuno-Oncology | 2019 |
| 163 | GreenCorrosionStop | Commercialisation of a unifying green VCI anti-corrosion paper for the manufacturing industry and logistics companies | 2018 |
| 164 | p38_InTh | Innovative therapeutic tools to ameliorate chemotherapy-induced cardiotoxicity | 2018 |
| 165 | IMPACCT | Improved Patient Care by Combinatorial Treatment | 2019 |
| 166 | PHARMS | Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies | 2019 |
| 167 | Sugar-Enable | Influenza Virus - Sugar Interactions, From Glycan Arrays To Better Vaccines | 2018 |
| 168 | inCITe | Seeing Citrulline: A Molecular Toolbox for Peptidyl Arginine Deiminases | 2019 |
| 169 | LeukemiaEnviron | SIGNALING PROPENSITY IN THE MICROENVIRONMENT OF B CELL CHRONIC LYMPHOCYTIC LEUKEMIA | 2019 |
| 170 | ONCOBIOME | Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. | 2019 |
| 171 | CRISPRsition | Developing CRISPR adaptation platforms for basic and applied research | 2019 |
| 172 | BiocatSusChem | Biocatalysis for Sustainable Chemistry – Understanding Oxidation/Reduction of Small Molecules by Redox Metalloenzymes via a Suite of Steady State and Transient Infrared Electrochemical Methods | 2019 |
| 173 | Cr Free REAL | Development and testing of innovative Cr Free solution for REmoval of Anodic Layers | 2019 |
| 174 | PsychAID | Psychiatric Disorders: ATX-inhibiting drugs as a new therapeutic option: Proof-of-Concept | 2019 |
| 175 | 20SInhibitor | Selective 20S proteasome inhibition for multiple myeloma therapy | 2019 |
| 176 | Human Repl Mech | Mechanisms of human DNA replication | 2019 |
| 177 | Kinaddict | Vulnerability of esophageal cancer to their addiction to kinase activities: evaluation and prediction of eSCC tumors responsiveness to kinase inhibitors. | 2019 |
| 178 | hsPCF-FRET | Real-time characterisation of neuropeptide binding to a membrane receptor involved in pain and ischemic stroke | 2019 |
| 179 | CM_GF | Biological relevance of the multiple infection unit as a novel target for antiviral development | 2020 |
| 180 | HONORLOGIC | The Cultural Logic of Honor and Social Interaction: A Cross-Cultural Comparison | 2019 |
| 181 | AR-DDR | Co-targeting androgen receptor signalling and DNA damage repair for precision therapy in advanced prostate cancer | 2019 |
| 182 | iRhomADAM | Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling | 2020 |
| 183 | MGLycan | Targeting hMGL-GalNAc interactions to reverse immune suppression in cancer | 2019 |
| 184 | PhotoStem | Photoswitching molecules for the spatiotemporal control of cancer stem cells with light | 2019 |
| 185 | SingCelCD | Single Cell approaches for the study of oncogenic processes during coeliac disease. | 2019 |
| 186 | 3D NKCC1 | Interdisciplinary approach to characterize the structure and the ion transport mechanism of NKCC1, a key target for brain disorders. | 2019 |
| 187 | IMMUcan | Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts | 2019 |
| 188 | TargetDUBs | Targeting ubiquitin processing in cancer and fibrosis: novel probes for the Ubiquitin Carboxy-Terminal Hydrolases | 2019 |
| 189 | MIMIC | Deciphering how microbiota modulate anti-tumor immune responses in checkpoint therapy | 2020 |
| 190 | FEN INHIBITORS | Development of Kinetoplastida Flap Endonuclease Inhibitors in Search for Novel Therapeutics | 2020 |
| 191 | MS4Drug | An Innovative Mass Spectrometry-Based Workflow for Drug Discovery | 2019 |
| 192 | PePiPOM | Peptide-functionalized POMs as biofilm disruption agents: searching for synergy in bactericidal materials | 2019 |
| 193 | LIBSED | Libiguins: a remedy for the treatment of sexual dysfunctions | 2019 |
| 194 | EPICAN | Inhibiting tumor cell plasticity by targeting the epigenome in breast cancer | 2020 |
| 195 | RespiriTB | Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors | 2019 |
| 196 | RespiriNTM | Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs | 2019 |
| 197 | UNPACK PD-L1 | Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells | 2020 |
| 198 | ProTeCT | Proteasome as a target to combat trichomoniasis | 2019 |
| 199 | TOPAS | Exploiting the Tumor Proteome Activity Status for Future Cancer Therapies | 2019 |
| 200 | CONNECT-2-CLINIC | Pannexin1 nanobodies for the clinical treatment of liver disease | 2020 |
| 201 | TWO-BIRDS | A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry | 2019 |
| 202 | FRAME | FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf | 2019 |
| 203 | TRACER | TRAF-STOP therapy to reduCe inflammation in athERosclerosis. | 2020 |
| 204 | AntiHelix | DNA helicases in genome maintenance: from molecular and cellular mechanisms to specific inhibitors as potential drugs | 2019 |
| 205 | TaMIE | Targeting MarA to Inhibit Efflux | 2019 |
| 206 | CYPNASH | Validation of a novel class of cyclophilin inhibitors for the treatment of non-alcoholic steatohepatitis | 2019 |
| 207 | CHANCE | Structure guided inhibition of IDOL to treat atherosclerosis and the metabolic syndrome | 2019 |
| 208 | G125 | A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency | 2019 |
| 209 | CSI AurkA-MYC | Conformational Shift Inducers (CSI): An atomistic level investigation of Aurora kinase A (AurkA)–MYC interaction and its distortion by CSI compounds | 2019 |
| 210 | Cenya | Ex vivo cell labelling for in vivo imaging applied to cell therapeutics | 2019 |
| 211 | Hydroptics | Photonics sensing platform for process optimisation in the oil industry | 2019 |
| 212 | EcoFoil | Innovative, sustainable and globally unique storage method for food preservation | 2019 |
| 213 | MEPHOS | Shaping the Mechano-Pharmacological properties of Microparticles and Extracellular Vesicles for the Treatment of Osteoarthritis | 2020 |
| 214 | MEISi | Druggable Small Molecule Inhibitor of MEIS Proteins | 2019 |
| 215 | STI-001 | Turn Cancer Immunotherapy Effective in Most Patients | 2019 |
| 216 | PARPinhibit | A systems biology approach to tackle PARP-inhibitors resistance and identify novel therapeutic targets to overcome it | 2020 |
| 217 | DECISION | DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES | 2020 |
| 218 | ISOLDA | Improved Vaccination Strategies for Older Adults | 2020 |
| 219 | DDREAMM | Dna Damage REsponse: Actionabilities, Maps and Mechanisms | 2020 |
| 220 | PANACHE | Production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases. | 2020 |
| 221 | EDUC8 | Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity | 2020 |
| 222 | inhibiTOR | Novel selective mTORC1 inhibitors | 2020 |
| 223 | Glue2Degrade | Therapeutic hijacking of E3 Ligases | 2020 |
| 224 | PP-MAGIC | (Photo-)Control of Persisters: Targeting the Magic Spot | 2020 |
| 225 | TESTIMONY | Tumor Endothelial Cells: Gatekeepers Of Anti-Tumor Immunity | 2020 |
| 226 | BRCAstem | Monitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells | 2020 |
| 227 | FBC predisposition | Unraveling novel Familial Breast Cancer (FBC) predisposition genes. | 2020 |
| 228 | NetriCan | Characterization of the role of netrin-1 in the regulation of the Epithelial-to-Mesenchymal Transition during tumor progression. | 2020 |
| 229 | TGF-BTB | Transforming Growth Factor – Bench To Bedside. Towards a better understanding of TGF-β isoform specific signalling in health and disease | 2020 |
| 230 | FluAttack | Validation of a novel antiviral drug candidate against influenza | 2020 |
| 231 | RegARcis | Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation | 2020 |
| 232 | RabTarget4Metastasis | Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast cancer | 2020 |
| 233 | ANTIBIOCLICKS | BioInspired Clicked Siderophore-Antibiotics | 2020 |
| 234 | PyroSuL | Pyrophosphate Surrogates with Low polarity as part of glycosyltransferase ligands | 2021 |
| 235 | ICG68-PROG | Imaging of c-Met aberrant cancers with Gallium-68 chelators for positron emission tomography | 2020 |
| 236 | DIM-CrIC | Decreasing Pancreatic Adenocarcinoma-related Inflammation using small molecule inhibitors of STING | 2020 |
| 237 | HT4PD | The role of the serotonin 5-HT4 receptor in motor and non-motor symptoms of Parkinson’s disease | 2021 |
| 238 | TARGETOF | Mass cytometry nanotools for intracellular target engagement. Towards precision medicine. | 2021 |